Blood 2018 Jun 13
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study.
Related Questions
The patient who has not responded to steroids, rituximab/bendamustine, and splenectomy?
New answer by Medical Oncologist at Cedars-Sinai Medical Center (March 17, 2021)
Some options include the following: 1. Bortezomib has about a 32% ORR described in this 2018 study (Blood). The study only gave one cycle of therapy which seems quite sho...